Start with the information that applies to you

The bBHC team is developing a physician-first approach to KHC patient access. The starting point is your own doctor and your individual medical situation—not an online treatment purchase.

Where an appropriate route can be established, a patient-specific review may lead to assessment at a qualified hospital or clinic in the country of treatment. Assessment in Korea is a separate possibility; international travel is not the only model being considered.

Choose your country of residence before continuing. Information about one country does not mean that the same treatment, payment arrangements or permissions apply elsewhere.

What this website can help you understand

Your next conversation. Prepare questions about established treatments, investigational options, uncertainty, costs and follow-up.

The review process. Understand what your physician would need to provide and what must be checked before a treatment decision.

Country-specific information. Find out whether this website provides general information, a professional enquiry route or details of a confirmed programme.

Current programme position

This website does not announce an open, universally available KHC treatment programme. An enquiry is not a reservation, an acceptance decision or permission to receive treatment. No patient should pay for treatment or make non-refundable travel arrangements on the strength of this website.

KHC remains investigational in the development programme described here. An access permission, where obtained, is different from a marketing authorisation. Benefit is uncertain, and important risks may not yet be known.

Choose your next step

Patients and families: select your country, then read the patient information appropriate for your location.

Healthcare professionals: use the professional enquiry route for a factual, case-appropriate response.

Someone who has already received treatment: use the safety and aftercare information provided by the treating institution. In an emergency, obtain local medical help immediately.

A physician-first approach

The proposed programme begins with a treating physician who believes that a patient-specific review may be reasonable. The physician provides a clinical summary, explains the established options already considered and identifies the question that needs to be answered.

The intention is to use an existing qualified hospital or clinic where the local route, product handling and medical arrangements permit this. Preferred sites or dedicated centres may be considered later. Their future development does not mean that a treatment network is already open.

Treatment locally and assessment in Korea are separate possibilities

A request for local treatment requires a local legal route, an appropriately authorised clinician and facility, and a permitted supply arrangement. A Korean assessment requires its own institution, programme and patient-specific checks. Neither route is created simply by a referral or a private payment.

The programme team must provide a written explanation of the country and facility being considered before you make a financial or travel commitment.

Six checks before a treatment decision

Medical suitability: your diagnosis, alternatives, current health and individual benefit–risk assessment.

Product readiness: the exact product, a released lot, appropriate testing and acceptable storage and handling.

Country permission: the route that permits the proposed use, including any authority, ethics or import requirements.

Facility readiness: a qualified treating team, appropriate pharmacy or cell-handling capability and emergency arrangements.

Financial permission: whether charging is permitted, who may charge, and your complete written quotation.

Safety and information arrangements: informed consent, follow-up, reporting responsibilities and appropriate handling of your records.

Separate from the formal approval programme

Patient access and the development work needed for future marketing applications are different activities. KHC’s development planning includes product definition, manufacturing information, assessment of historical records and prospective studies. No approval date or successful regulatory outcome is promised.

Information collected during access may contribute to safety knowledge when collected and used appropriately. It does not automatically replace the studies needed to establish benefit for a specific condition.

Begin with your usual doctor

Discuss your diagnosis, what has already been tried and which established options remain available. Ask whether your condition needs urgent attention and whether looking at an investigational option could delay care that you need now.

Your doctor does not need to recommend KHC before asking a factual question. The purpose of a review is to assess whether further consideration is justified; declining or deferring a request is a possible and appropriate outcome.

What you should receive before agreeing

A proposed treatment should be explained in terms you understand. The written information should identify the exact product, treating physician and institution; why it is being considered; the evidence and its limitations; the dose, route and schedule; and the risks, alternatives and follow-up.

You should also receive an itemised quotation, payment and cancellation terms, and an explanation of who will provide and pay for care if a complication occurs. Ask for an interpreter or translated documents when needed.

Questions worth taking to the consultation

• What evidence relates to the same product and to people with my condition?
• How many patients did not improve, became worse or could not be followed up?
• What serious or delayed problems are known, and what remains uncertain?
• What would you recommend if I decide not to proceed?
• Who will look after me during treatment and after I return home?
• What would make you stop treatment or advise against another administration?

Your choice remains yours

You may ask for more time, involve someone you trust or seek an independent medical opinion. A family member may help with communication, but records and treatment decisions require the appropriate patient permission or representative authority.

A decision not to proceed should not prevent access to your records or to an explanation of the review. Financial discussions must not determine the medical judgement. Further treatment is never automatic.

Do not delay urgent care

This programme is not an emergency service. A serious infection, sudden breathing problem, chest pain, new weakness or another urgent change needs prompt local medical assessment. Do not wait for a website reply.

1. Ask for the right information

Select your country and identify whether you are a patient, authorised representative or healthcare professional. The first enquiry should contain contact and routing information only. Do not send medical records, photographs, passport details or payment information through a general contact form.

2. Confirm whether a review route exists

The programme team checks whether the enquiry can be considered for a named country and institution. Where no appropriate route is available, the reply should say so. Your request must not be turned into a promise of access in another country.

3. Authorise a medical-record review

If further review is appropriate, you and your physician receive instructions for a secure record transfer. The request should explain which records are needed, who will receive them and any relevant international transfer. Permission to review records is not consent to treatment or publicity.

4. Complete the clinical and programme assessment

A clinician reviews the diagnosis, previous care, current options, comorbidities, medicines and relevant tests. Additional specialist assessment may be needed. In parallel, the programme checks the product, country route, facility, proposed costs and follow-up arrangements.

5. Receive a written outcome

The outcome may be proceed to further assessment, defer pending information, or unable to offer access. A preliminary positive review is not final clearance to treat. Any conditions and outstanding checks should be explained.

Where treatment can be considered, you receive the final medical information, consent documents, quotation and practical plan before deciding. You should have time to ask questions.

6. Treatment and follow-up, only after final clearance

The responsible treating institution confirms the appointment only when the required checks are complete. Product quality or a change in your health can still require postponement or cancellation. Follow-up responsibilities must be agreed with you and, where appropriate, your home clinician.

How long does it take?

There is no single guaranteed review or treatment timeline. It depends on the available records, clinical complexity, country requirements, facility readiness and product availability. The team should tell you what the next step is rather than give an unsupported treatment date.

Different routes have different payment rules

Some locally permitted medical-care arrangements may allow a patient to pay privately. Other routes permit only specified cost recovery, or require different funding arrangements. A clinical trial has its own financial and consent framework.

The programme must confirm the payment position for the particular country, institution and route. There is no universal KHC private-pay price or worldwide treatment package offered through this website.

Your quotation should make the total understandable

The written quotation should identify each payee and currency and distinguish the product or access charge from professional fees, facility and administration charges, screening tests, monitoring, shipping or handling where applicable, and follow-up.

It should also explain what is not included: travel, accommodation, interpretation, companion costs, additional investigations, care after returning home and potential treatment of complications. Taxes, currency conversion, payment deadlines and changes in the proposed care should be addressed.

Before making a payment

The programme’s proposed policy is that treatment payments are not requested until medical eligibility and the country, product, facility and payment checks are complete. Any separately proposed fee for an assessment must be lawful, disclosed in advance and clearly distinguished from a treatment deposit. It must not buy priority or guarantee acceptance.

You should receive written cancellation terms for medical ineligibility, product or facility cancellation, your own cancellation and changes to travel. Those terms should explain how any refund is calculated and when it is paid. Your mandatory legal rights are not removed by a website disclaimer.

Insurance and financial assistance

Do not assume that a public health system, insurer or travel policy will pay. Seek a written coverage decision from the relevant payer before committing. No hardship fund, financing arrangement or reimbursement entitlement is announced on this page.

Paying more does not establish greater benefit

The price, number of injections or number of treatment blocks does not demonstrate effectiveness. Repeat treatment requires a new medical and safety decision and a new cost explanation. No outcome-based refund promise, automatic subscription or discounted treatment bundle is offered here.

Before arranging travel

Ask your own doctor whether travel is medically appropriate. Wait for written confirmation of the proposed institution, responsible clinician, medical-review outcome and lawful route before making non-refundable bookings.

The institution should explain the expected assessment and treatment schedule, how long you may need to remain nearby, whether a companion is advisable and what could change the plan. Do not assume that a short visit is suitable for your condition.

What to clarify with the institution

Confirm accessibility needs, interpretation, transport after a procedure, accommodation close to the facility and how to obtain urgent help. Immigration requirements and the ability to travel with prescribed medicines need a separate current check; the programme cannot guarantee entry to a country.

An enquiry does not authorise you to carry or personally import a cellular product. Any permitted supply must use the responsible licensed parties and controlled handling arrangements for that route.

Before leaving the treating facility

Obtain a discharge summary, the details of what was administered, medicine instructions, the follow-up schedule and a working clinical contact. Ask what symptoms need urgent care and which hospital should manage a complication.

Your usual clinician should receive the information needed to support you after treatment, with appropriate authorisation. A general website or coordination inbox is not a substitute for a clinical handover.

Follow-up is part of the decision

The schedule should match the product, route, condition and programme requirements. It may include early safety contact, examinations, laboratory tests and longer-term monitoring. Your final patient plan—not a general website timetable—sets out the required visits.

Report a new illness, hospitalisation, reaction or change in medicines even when you are unsure whether it relates to treatment. Do not stop prescribed care or take additional treatment based only on website information.

When arrangements change

A change in your health, unavailable released product, a facility problem or a regulatory issue may mean treatment is postponed or not offered. The written financial agreement should explain the associated cancellation and additional-cost position before you travel.

What KHC is described as

The project describes KHC as a donor-derived cellular product obtained from umbilical-cord tissue, with no genetic modification reported. “Donor-derived”, or allogeneic, means that the cells come from another person, rather than from the intended recipient.

The exact current cell identity, manufacturing process, formulation and clinical presentation need to be specified in the controlled product dossier. This general description does not establish that the product is exempt from medicines or biological-product regulation.

What the historical Korean experience can—and cannot—tell us

The company reports approximately 30 years of clinical-use experience in Korea. The development task is to preserve and assess the underlying records, including which product version was used, how patients were selected, what other care they received and whether outcomes and adverse events can be verified.

Earlier treatment experience must not automatically be attributed to the current product. Missing follow-up, incomplete records and uncontrolled observations limit the conclusions that can be drawn. A long history of use is not proof that a treatment works for a particular condition or that serious risks do not occur.

Quality information is product-specific

Manufacturing and quality information are reported to exist in Korea and require consolidation and review for the global programme. A statement that manufacturing follows GMP is not itself evidence of a current licence, a satisfactory inspection or release of the lot intended for an individual patient.

The clinical team needs the actual product information and the relevant quality disposition before considering administration.

Building an evidence package

The planned work includes defining the current product; connecting historical patient and manufacturing records; assessing nonclinical and clinical information; identifying gaps; and agreeing an appropriate prospective development strategy with the relevant authorities.

Future regulatory applications would need evidence for the specific proposed indication. Work in one condition does not establish benefit in another. No regulatory approval date, study outcome or universal treatment claim is made here.

Professional questions

Healthcare professionals may request a factual response on the current dossier, evidence limitations and programme status. Information should be supplied through the appropriate professional process and remain subject to local communication rules.

Start with the question you need answered

A professional enquiry may concern product characterisation, available evidence, safety information, the status of a country route or whether a particular clinical situation warrants further review.

The enquiry is not a product order. It does not reserve stock, establish patient eligibility or authorise import, supply, administration or charging.

General scientific enquiries

Provide your name, role, professional registration jurisdiction, institution and professional contact details. Indicate the topic and the country in which you practise. Do not include identifiable patient records in the first contact.

Professional status and the appropriate communication route will be checked before controlled materials are released. Some information may not yet be available in a reviewed form. The reply should distinguish source-verified evidence from company-reported experience and development assumptions.

A patient-specific request

Where a review route is available, the treating clinician is asked to explain the confirmed diagnosis, severity, previous care and response, remaining established options and reason for the request. Relevant comorbidities, medicines, allergies, tests and specialist opinions are needed.

Identifiable information should be sent only after the necessary authorisation and secure transfer arrangements are established. A local physician’s request does not remove the requirement for country, product, facility, financial and safety clearance.

What professional materials may cover

The information package may address current product definition, donor and manufacturing controls, lot release, available nonclinical and clinical information, known and potential risks, programme-specific patient criteria, handling and administration requirements, follow-up and reporting responsibilities.

No document should be assumed complete or approved merely because it appears in a professional portal. Version, scope, limitations and country of use should be clear.

Protect continuity of care

Do not delay necessary care while awaiting a response. Explain that a request may be declined or deferred and that the patient should not book travel or pay for treatment on the basis of a preliminary discussion.

Commercial relationships must not determine clinical eligibility or the decision to repeat treatment.

Clinical trials

This website does not currently publish a verified recruiting KHC clinical-trial listing. A trial should be described only after its identity, sponsor, participating sites, regulatory and ethics status, registration and recruitment position have been checked.

A future trial listing should identify the study and the population being considered, explain that screening may lead to non-enrolment, and provide an approved contact. It should not use a trial listing to advertise unapproved benefits.

Patient access outside a trial

An access route, where available, is considered separately from research enrolment. A decision to provide treatment, collect safety information or evaluate historical records does not by itself turn the activity into an approved clinical trial.

Patients should be told which activity they are entering, which permissions apply and how their records will be used. Research use beyond necessary care and safety must be addressed through the appropriate governance and privacy process.

Current status announcements

A country listing is not an announcement that the country is open for treatment. An active programme notice must identify the country and treating institution, the approved scope of the programme, the responsible contact and the date the information was checked.

Availability may change. A programme may pause because of safety, product, institutional, legal or operational considerations. Previously issued information should not be treated as a permanent entitlement to access.

Why there is no broad “conditions we treat” menu

The project has explored several potential therapeutic areas. That does not establish authorised access, suitable dosing or demonstrated benefit in each one. A condition-specific page needs its own evidence, patient criteria, risk information and local publication approval.

What the country pages mean

These pages explain the information and review position for the markets considered in the KHC access plan. They are not a list of countries in which KHC is approved or currently available.

Korea: institution- and treatment-plan-specific assessment information.

United States, United Kingdom and European Union: factual regulatory-status and professional-enquiry information, not a private-pay product offer.

Australia and Singapore: separate public service-information pages without product promotion.

New Zealand, Canada, Japan and South Africa: country-specific practitioner-led information, with no KHC authorisation or active treatment site presumed.

Israel, Brazil and the United Arab Emirates: holding information while product-specific local arrangements remain unconfirmed.

Local treatment is not the same as overseas access

A medical review in your own country requires an applicable local pathway. Travel to another country requires a separate decision and does not authorise local import, follow-up treatment or product promotion at home.

A country selector helps present relevant information; it does not create legal permission or replace the treating institution’s review.

A country not listed here

No local programme is implied. Your clinician may request a general regulatory or scientific response, but a new country requires its own assessment before patient-specific access can be considered.

The programme position

Korea is part of the KHC access planning, including the possibility of international patients attending a Korean medical institution. This page does not confirm an open programme, an authorised treatment indication or acceptance by a particular facility.

Before a patient-specific offer is made, the institution must confirm the exact lawful route and its authority to provide the proposed treatment.

What a Korean treatment plan means

Korea’s advanced regenerative medicine framework provides for designated institutions and treatment-plan review. The treatment-plan provisions address matters including the proposed cells and administration, patient selection, consent, safety management, follow-up, compensation arrangements, personal information and the basis of treatment charges. Completion of the applicable process is not equivalent to a product marketing authorisation. [S10]

For KHC, the institution and product-specific position must be confirmed from the actual documents—not inferred from the existence of that framework.

Before an international patient travels

You should receive the institution’s legal name and address, the responsible clinician, the written review outcome and the programme details relevant to your condition. The proposed product, route, schedule, risks, uncertainties and alternatives should be explained in your language or with appropriate interpretation.

Confirm the expected length of stay, emergency arrangements, care after returning home and all known charges. International-patient coordination, where provided, is separate from the decision that treatment is medically and legally appropriate.

Private payment

A written quotation must match the permitted programme and identify who receives each payment. Ask how costs change if screening finds you unsuitable, the product cannot be used or treatment is cancelled. A payment does not guarantee treatment or a clinical result.

Your next step

Discuss the question with your usual doctor. Where a review route is confirmed, the doctor can provide an authorised clinical summary through the approved process. Do not send full records or arrange travel from this page alone.

No US treatment offer

The programme materials describe KHC as investigational. This page does not announce an active US expanded-access programme, a recruiting US trial or an FDA authorisation for a particular patient.

Your clinician may request a factual response about development status. A website enquiry cannot authorise treatment, importation or shipment to a US clinic.

A possible investigational route must be established first

FDA expanded access can provide a route to an investigational drug or biological product for patients with serious or immediately life-threatening disease when the relevant criteria are met. Medical justification, the available alternatives, benefit–risk, sponsor cooperation and the impact on clinical development are part of that assessment. Appropriate FDA and institutional processes are required. [S01]

This describes the framework, not a finding that KHC or a particular patient qualifies.

Payment is not a shortcut

Charging for an investigational product under an IND requires FDA authorisation and is limited by the applicable cost-recovery rules. It is not a general commercial private-pay entitlement. Medical-service and facility charges must be considered separately and explained accurately. [S02]

No US treatment price, deposit, subscription or guaranteed-access fee is offered on this page.

Questions for your clinician

Ask which established options and clinical trials remain available, whether a request for investigational access is medically justified, and who would be responsible for the necessary submissions, consent and monitoring.

An overseas treatment opportunity should not be interpreted as FDA endorsement or as permission to bring a product back for administration in the United States.

Right to Try and future availability

This website does not offer KHC under Right to Try or state that the product meets that route’s eligibility requirements. A future access-policy announcement will require a separate documented review.

Keep following the advice of your treating team. Do not delay necessary treatment while waiting for information about a programme that has not been confirmed.

Information is not an offer of an unlicensed medicine

This page is limited to factual status and professional-enquiry information. The MHRA states that an unlicensed medicine must not be advertised, including through promotional website material. A professional audience is not, by itself, an exemption for unlicensed-product advertising. [S06]

KHC is not offered here for purchase, private booking or administration in the United Kingdom.

A clinician-led question

A UK clinician may ask for a factual response on product status, evidence or a possible patient-specific route. No individual’s records should be sent until the appropriate authorisation and secure process are in place.

The review must establish whether the proposed product and use can lawfully be supplied and administered. It should not assume that an ordinary “specials” arrangement automatically applies to an imported cellular product.

Special clinical need and other mechanisms

The UK specials framework concerns unlicensed medicines supplied to meet a genuine special clinical need through the applicable lawful supply arrangements. The specific product classification, manufacturing or import position and clinical governance still require confirmation. [S07]

This page does not announce a KHC Early Access to Medicines Scheme opinion or suggest that that scheme is immediately available.

Costs and continuity of care

No NHS funding, private-insurance payment or private-pay availability is promised. Any lawful patient-specific arrangement would need a complete cost explanation, named responsible clinicians and a practical monitoring and emergency plan.

Assessment or treatment abroad would require a separate review. It would not create permission for supply in the UK or a right to follow-on administration by a UK clinician.

Your next step

Discuss established options with your usual clinician. A professional request can seek clarification; it is not a commitment to treatment or proof that a UK route exists.

No European marketing authorisation is implied

KHC is not presented here as an authorised marketed treatment in the European Union. This regional page provides general status information and does not offer a product, a price or a treatment appointment.

A proposed cellular product may fall within the advanced-therapy framework; the exact classification must be confirmed from the product, processing and intended use.

National access and group programmes are different

Compassionate use under the European framework and national patient-specific mechanisms have different conditions. Member States are responsible for their own implementation. EMA’s compassionate-use framework does not itself create a universal named-patient permission or a right to obtain treatment. [S08]

The relevant country, product, clinical situation, institution and supply chain need a separate review before any offer is considered.

Hospital exemption is not a global distribution model

An advanced therapy used under a hospital exemption is subject to the applicable national framework. A hospital’s involvement does not turn an unapproved imported product into a freely marketable therapy, and one country’s arrangement does not automatically permit use elsewhere. [S09]

No KHC hospital-exemption arrangement is announced on this page.

For patients and clinicians

Start with the patient’s usual physician. A professional enquiry should identify the country of intended treatment and ask for factual status information before records are requested or costs discussed.

Where a lawful review becomes possible, the patient should receive information in an appropriate language, a clear description of alternatives and uncertainty, and the identities of the treating institution and the parties responsible for follow-up.

Country and payment details still matter

There is no EU-wide private-pay quotation or reimbursement promise. Import, prescribing, treatment charges, public communications and medical-record transfers must be checked locally.

The UK and Switzerland have separate regimes and are not included in this page’s EU marketing-authorisation statements. A request involving another jurisdiction requires its own review.

Begin with your treating practitioner

Your usual practitioner is best placed to discuss your condition, established care and whether a further professional opinion may be appropriate. This information service does not diagnose conditions, recommend a particular treatment or make medical decisions.

No treatment is advertised, sold or booked through this page.

What an initial enquiry can cover

You may request general administrative information about contacting the medical-information team or ask how your practitioner can raise a professional question. Please provide only your name, country, preferred language and contact details.

Do not submit a diagnosis, test result, clinical photograph or complete medical record through a general enquiry channel. Where a professional review is appropriate, you will be told how information can be transferred through the relevant authorised process.

For healthcare professionals

A registered practitioner may request a non-promotional scientific or regulatory response through the professional-information process. Professional identity, jurisdiction and the purpose of the enquiry are checked before any controlled material is supplied.

A professional request does not establish that an intervention is available, that a patient is eligible or that any necessary permissions have been obtained.

Your decision and ongoing care

Continue to discuss treatment decisions with your own practitioner. Do not stop prescribed care, make payments or arrange medical travel on the basis of this page. Any further assessment needs its own clinical, legal, practical and financial information.

Privacy and urgent concerns

This is not an emergency service. For an urgent medical problem, contact your local emergency service or treating team. For an existing care arrangement, use the clinical contacts provided by that institution.

General enquiries should not include sensitive information about someone else without appropriate authority. Contact instructions and the privacy notice must be reviewed before sending records.

Current KHC position

This page does not announce an approved New Zealand KHC medicine or a confirmed local patient-access programme. Your prescriber may request factual information about whether any further review is possible.

A reply should distinguish what is known about the product from what remains to be confirmed for local use.

Unapproved-medicine routes require specific responsibilities

Medsafe describes circumstances in which authorised prescribers and suppliers can obtain or supply an unapproved medicine for a particular patient. Its current guidance includes sections 25, 29, 29A and 29B, with responsibilities depending on the route and the prescriber or supplier involved. These mechanisms do not confer marketing approval. [S11]

The proposed cellular product, importer, supplier and professional responsibilities must be assessed specifically. This page is not an import authorisation.

Information for the patient

Before agreeing to an unapproved option, ask your prescriber why it is being considered, what established alternatives remain, which evidence relates to the current product and what safety information is missing.

The clinical team should explain the proposed treatment, uncertainty, follow-up and who will respond to a problem. Your prescriber’s involvement is essential, but it does not by itself establish product quality or a permitted supply arrangement.

Costs and records

No local price, subsidy or insurance coverage is promised. A proposed payment must be assessed against the actual route, and the complete cost must be explained before commitment.

If your prescriber is invited to provide records, use the authorised secure process. Supply and reporting records must be handled by the responsible parties; sending information to the programme is not the same as completing those duties.

Your next step

Ask your prescriber to seek a factual country-status response first. Do not arrange personal importation or assume that treatment received overseas may be continued in New Zealand without a separate local decision.

No Canadian availability is presumed

This page does not announce a Canadian KHC marketing authorisation, an accepted Special Access Program request or an activated treatment site. A practitioner can ask for factual product and programme information before deciding whether further consideration is appropriate.

What the Special Access Program does

Health Canada’s Special Access Program allows practitioners to request certain non-marketed drugs for serious or life-threatening conditions when conventional treatments have failed, are unsuitable or are unavailable. The request is made by the practitioner, not by the patient as an online purchaser. Authorisation and manufacturer supply are separate considerations. [S05]

The existence of SAP does not establish that KHC or any particular patient qualifies.

What your practitioner would need to discuss

The discussion should include the medical rationale, established options, evidence relating to the proposed product, important uncertainties and the plan for monitoring and reporting. The patient should know who is responsible for treatment and follow-up.

A patient-specific review should not begin with a treatment deposit. Records should be supplied only after appropriate patient permission and secure transfer instructions.

Costs and coverage

Health Canada notes that a manufacturer may supply a product without charge or may charge, and payment arrangements can vary. SAP is not a promise of insurance or provincial coverage. [S05]

For any proposed KHC arrangement, the permitted charge and the full patient cost need to be confirmed in writing, including professional fees, facility care, follow-up and additional expenses.

Your next step

Talk with the practitioner responsible for your care. A factual enquiry can establish whether there is a relevant programme response; it cannot guarantee authorisation, supply or benefit.

An overseas assessment is a separate matter and should not be interpreted as Canadian regulatory endorsement or permission for domestic administration.

Current programme status

Japan is a potential country for further programme assessment. This page does not announce a Japanese KHC treatment plan, a participating clinic, a product approval or permission to begin treatment.

A clinician or institution may request factual information about the product and the development of an appropriate local route.

Two different regulatory questions

Japan’s Ministry of Health, Labour and Welfare describes the Act on the Safety of Regenerative Medicine framework for the provision of regenerative medicine, alongside the separate medicinal-product framework. Provision plans, committee processes and cell-processing facility requirements must be considered as applicable. [S12]

For KHC, the classification and required procedures need to be established from the actual donor-derived product, processing and proposed clinical use. A submitted plan or committee review must not be presented as proof of efficacy or as a product marketing approval.

Before a patient-specific offer

The responsible institution should identify the clinician, legal route, plan scope and relevant review position. The proposed product, preparation, route and schedule must be clear. A patient should receive balanced information about evidence, alternatives, risks and follow-up.

A description of historical use in Korea is not a substitute for the Japanese institution’s own responsibilities.

Private payment and travel

Private medical-care charges, where permitted, need an itemised explanation and clear cancellation arrangements. This page does not offer an insured benefit, a private-pay package or a price per administration.

International patients should clarify interpretation, travel fitness, length of stay, emergency arrangements and the handover to their usual clinician. No non-refundable booking should be made before written confirmation of the relevant assessment arrangements.

Your next step

A professional enquiry should identify the Japanese institution and clinical question being considered. An individual review can proceed only when the country, product, clinical and operational requirements are confirmed.

Information, not a treatment offer

This page does not advertise a therapeutic product, announce a treatment programme or invite online purchase. A patient’s own clinician should lead discussions about diagnosis, established options and whether a further professional enquiry is appropriate.

General enquiries

An initial administrative enquiry should contain only the contact details needed for a response, your country and preferred language. Please do not include identifiable clinical records or payment information.

The team should explain whether the request can be directed to an appropriate professional-information contact. A response is not confirmation of eligibility, local availability or regulatory permission.

Professional requests

Healthcare professionals may identify their registration jurisdiction, institution and the factual scientific or regulatory question. Professional status and the applicable communication rules must be checked before controlled information is released.

A professional login is not, by itself, permission to promote an unregistered product. Some requests may need to be limited, deferred or handled through a different lawful scientific process.

Before any separate clinical decision

An institution considering a patient-specific intervention would need to establish its own medical, regulatory, supply and monitoring position. Any proposed care should be explained separately, including alternatives, uncertainty, known costs and responsibilities.

No special-access authorisation, price, reimbursement arrangement or hospital participation is announced on this page.

Existing care and urgent help

Continue to follow the advice of your usual clinical team. For urgent symptoms, obtain local medical help; do not wait for an administrative reply. Patients already under an institution’s care should use that institution’s clinical contact and aftercare instructions.

Current KHC position

No South African KHC authorisation, treatment site or patient-access programme is announced here. An appropriately qualified practitioner may request factual information on the product and the possibility of a local review.

The Section 21 framework

SAHPRA describes a process under Section 21 for the authorised use of specified unregistered medicines. A treating practitioner applies, and an authorisation may be limited by matters such as the product, purpose, quantity, person or institution and period of use. [S14]

This does not establish that a particular cellular product is eligible or that an application will be accepted. Classification, supporting evidence and any additional requirements must be checked for KHC.

What a clinical request should explain

The practitioner should identify the clinical question, established care already provided, available alternatives and the evidence needed for a benefit–risk assessment. A potential treating facility needs appropriate product-handling, monitoring and emergency arrangements.

Patients should receive a clear explanation of investigational status, uncertainty, risks and follow-up before making any decision.

Costs and supply

A regulatory application or authorisation is not a general permission to advertise or charge any chosen price. The proposed payment, import and supply arrangements must be confirmed separately, together with the full patient quotation.

No local insurance payment or public funding is promised. Do not organise personal importation or arrange administration through an unqualified intermediary.

Your next step

Ask the practitioner responsible for your care to request country-status information before sending identifiable records. The first question is whether a lawful and medically appropriate review can be considered—not how quickly a treatment can be purchased.

Current position

The project has considered Israel as a possible future country for local assessment. Before a patient-specific request could proceed, the responsible team would need a current product-specific opinion on the legal route, an appropriate institution and clinician, and confirmation of import, supply, consent, monitoring and charging requirements.

References in planning documents to a named-patient or unregistered-medicine mechanism are not an authorisation for KHC. This page does not announce a Ministry of Health permission or a recognised treatment site.

What a general enquiry can do

A healthcare professional may ask for a factual statement of the current country position. An initial response should identify whether further assessment is possible and what remains unconfirmed. It is not a prescription, import permission or treatment acceptance.

Information and costs

Do not send detailed medical records until an authorised review process and privacy arrangements have been explained. No local treatment price, deposit, reimbursement entitlement or guaranteed review date is offered here.

If a programme is established later, patients should receive the institution’s identity, responsible clinician, exact treatment proposal, balanced evidence and risk information, lawful route, complete quotation and follow-up arrangements before deciding.

Your care now

Continue to discuss your care with your usual physician and do not delay established treatment while awaiting information. An overseas assessment would be a separate decision, not a substitute for local permission.

For an urgent medical issue, seek local clinical help rather than waiting for an administrative reply.

Current position

Brazil remains a country for further regulatory and institutional assessment. Any proposed access would require confirmation of the classification of the current product and the appropriate national mechanism, together with the responsibilities of the local institution, sponsor or importer.

A compassionate-use or expanded-access label must not be used to imply a general private-pay entitlement. The proposed funding and supply model would need to be reviewed for the particular route before costs could be discussed with a patient.

What a general enquiry can do

A healthcare professional may ask for a factual statement of the current country position. An initial response should identify whether further assessment is possible and what remains unconfirmed. It is not a prescription, import permission or treatment acceptance.

Information and costs

Do not send detailed medical records until an authorised review process and privacy arrangements have been explained. No local treatment price, deposit, reimbursement entitlement or guaranteed review date is offered here.

If a programme is established later, patients should receive the institution’s identity, responsible clinician, exact treatment proposal, balanced evidence and risk information, lawful route, complete quotation and follow-up arrangements before deciding.

Your care now

Continue to discuss your care with your usual physician and do not delay established treatment while awaiting information. An overseas assessment would be a separate decision, not a substitute for local permission.

For an urgent medical issue, seek local clinical help rather than waiting for an administrative reply.

Current position

The United Arab Emirates is an exploratory market in the project plan. The applicable national and emirate-level responsibilities, product classification and permissions for the proposed institution would need to be established before patient-specific access is considered.

A clinic’s general licence, a medical-tourism service or an overseas programme does not establish that a particular cellular product may be imported or administered. No authority endorsement, local treatment partner or approval timeline is represented here.

What a general enquiry can do

A healthcare professional may ask for a factual statement of the current country position. An initial response should identify whether further assessment is possible and what remains unconfirmed. It is not a prescription, import permission or treatment acceptance.

Information and costs

Do not send detailed medical records until an authorised review process and privacy arrangements have been explained. No local treatment price, deposit, reimbursement entitlement or guaranteed review date is offered here.

If a programme is established later, patients should receive the institution’s identity, responsible clinician, exact treatment proposal, balanced evidence and risk information, lawful route, complete quotation and follow-up arrangements before deciding.

Your care now

Continue to discuss your care with your usual physician and do not delay established treatment while awaiting information. An overseas assessment would be a separate decision, not a substitute for local permission.

For an urgent medical issue, seek local clinical help rather than waiting for an administrative reply.

A new country needs its own review

A healthcare professional may request a factual response identifying whether the programme has assessed the relevant country. Treatment cannot be presumed lawful because a similar product or an overseas programme exists elsewhere.

The review needs to consider the exact product and proposed use, applicable authority and ethics requirements, the supply and import chain, the institution and clinicians, advertising, charging, privacy and follow-up.

What to provide first

For a general enquiry, provide your country, professional or patient/representative role, preferred language and contact details. Do not send clinical records until the team confirms an appropriate process.

There is no guarantee that a new country route will be pursued or that a timeframe can be provided. Patient demand does not replace product, medical or legal readiness.

Keep your treating physician involved

Discuss your established options and any urgent needs with your own clinician. Do not pay a third party who claims that access can be guaranteed before the programme and institution have confirmed the arrangement in writing.

Is KHC an approved treatment?

The project materials describe KHC as investigational and not approved in the United States or European Union. No other country’s product approval is asserted by this website. A local access or treatment-plan permission, where obtained, must be described separately from marketing approval.

Does an enquiry mean I have been accepted?

No. It is a request for information or review. There may be no appropriate programme, insufficient information, an unsuitable benefit–risk balance or an established option that should be considered first.

Can my own doctor contact the programme?

Yes, where the country-appropriate professional enquiry channel is available. The first request should identify the professional and clinical or scientific question without sending identifiable records through an unsecured channel.

Must I travel to Korea?

Not necessarily. The proposed model considers physician-led assessment at qualified local facilities where a lawful route can be established. Korea is a separate potential assessment location. Neither is guaranteed.

Which conditions are eligible?

There is no universal eligibility list. A condition can be considered only against the exact programme, evidence, local route and medical criteria. A condition discussed in development planning is not automatically a condition for which treatment is available.

What does the Korean clinical history prove?

Company-reported historical experience may help inform further work when the records are traceable and reliable. It does not establish that all earlier patients received the current product, that every adverse event was captured or that benefit is proven for your condition.

Could treatment fail or cause harm?

Yes. There may be no benefit, your illness may progress, and serious or delayed problems may occur. The final medical information needs to explain the risks and uncertainties for the exact product and proposed use; their frequency must not be invented.

Is “not genetically modified” the same as low risk?

No. Risk and regulatory classification depend on more than genetic modification. The exact cells, processing, route, dose, patient and available evidence all matter.

Will a payment make access more likely?

A payment must not determine the medical decision. It also does not create regulatory permission or guarantee supply. No priority-access fee or treatment reservation is offered through this website.

Can I obtain a price now?

A useful patient quotation needs a confirmed route, institution and proposed care plan. Planning figures or the price paid by another patient are not your quotation. Ask for the total, the exclusions and the cancellation terms.

Will I need repeated treatment?

That cannot be answered from this website. Any repeat requires a fresh medical and safety review, continued lawful access and appropriate product availability. A financial model is not a treatment schedule.

May I stop my existing medicines?

Do not change prescribed treatment because of this website. Discuss any proposed change with the clinicians responsible for your care.

What happens to my records?

The initial public enquiry should not collect detailed medical information. If a review is appropriate, you should receive a privacy notice, record-transfer instructions and an explanation of the recipients and purposes before records are requested.

Is agreeing to a review the same as agreeing to research or publicity?

No. Record review, treatment, optional research and any use of your story or image are different matters. Relevant permissions must be addressed separately. A publicity consent cannot make an otherwise prohibited advertisement lawful.

Can a family member enquire for me?

A family member can seek general information. Access to identifiable records or decisions on your behalf requires appropriate authority. Where decision-making capacity is in question, the clinical team must follow the applicable process.

What should I do if I become unwell after treatment?

Follow the treating institution’s instructions and seek urgent local care when needed. Tell the treating team about a new problem even when its relationship to treatment is uncertain. Do not wait to complete a website form.

What we need at this stage

Your name, email address, country of residence, preferred language and whether you are a patient, authorised representative or healthcare professional. You may select an enquiry category: general programme information, professional information, privacy, accessibility or an administrative complaint.

Do not include your diagnosis, medical history, clinical photographs, passport or payment details in this first form. If a medical review can be considered, you will receive separate instructions.

What happens next

A general enquiry is used to identify the relevant information route. A reply may ask your physician to contact the team, explain that further review is not currently available or request clarification of a non-medical administrative point.

No eligibility, treatment, product allocation or appointment is created by sending an enquiry.

Contact permission

By asking for a reply, you authorise contact about this enquiry. This is separate from consent to receive marketing messages, release medical records, participate in research or receive treatment. No marketing subscription is included in the initial form.

Important service information

The published service must identify the responsible legal operator, working contact details, ordinary response hours and the appropriate privacy contact. A general inbox is not an emergency service and must not be described as continuously monitored unless that service is actually in place.

Review-edition notice: the form shown in this prototype is disabled. It does not send, save or acknowledge a real enquiry. Use fictional details only when reviewing the design.

If the situation is urgent

Contact your local emergency service or the treating institution’s emergency team immediately. Take the treatment information or patient card with you when possible. Do not wait for the programme coordination team or for a report form to be complete.

New severe breathing difficulty, chest pain, sudden neurological symptoms, a serious allergic reaction or another major deterioration should not be treated as a routine administrative enquiry.

Reporting a concern after treatment

Tell the treating clinician about a new illness, reaction, hospitalisation, medicine change or other unexpected problem, even if you are unsure that treatment caused it. Safety information can still be important when another explanation is possible.

The reporting team may ask for the treatment date, institution, product or lot details if known, what happened, when it began, medical care received and a contact for follow-up. A patient programme identifier should be used where possible; do not post identifiable information in public comments or social media.

A product-quality concern

A damaged container, unexpected appearance, missing label, handling problem or possible temperature excursion must be raised with the institution’s responsible clinical or pharmacy team. Only the responsible authorised team should decide whether a product may be used. Patients should not handle or attempt to repair product packaging.

What a live safety page must provide

Before a patient programme opens, patients and clinicians must receive verified clinical and safety-reporting contacts, an escalation route and any relevant local authority reporting information. These are part of the treatment documents as well as the website.

Review-edition notice: no live KHC safety intake is connected to this prototype and no round-the-clock contact has been supplied for publication. Patients already treated should use the contact details given by their treating institution. This prototype must not replace that service.

Privacy and safety records

A safety report is not a marketing consent. The responsible team may need to retain and share relevant information for care, safety assessment or legal reporting, subject to the applicable privacy notice and safeguards.

1. Who is responsible

The website operator and the entity responsible for an enquiry must be identified as [LEGAL ENTITY, REGISTERED ADDRESS AND PRIVACY CONTACT]. A treating institution may be independently responsible for clinical care and its medical records. Where responsibilities are shared, the relevant arrangement and contact must be explained.

This review edition does not connect to a patient database or accept real submissions. Its disabled forms are for design review only. This draft is not a claim that a live service or particular certification is already in place.

2. Information used for a general enquiry

The proposed first-contact form asks for a name, contact email, country, preferred language, role and enquiry category. Its purpose is to direct and answer the request. It should not collect diagnoses, clinical files, photographs or payment information.

The live service must also describe technical records generated by its hosting and security systems, including the actual categories and retention. Those systems have not yet been identified in this draft.

3. Medical information for an authorised review

Where a review is appropriate, the responsible clinical team may request relevant records from you or your authorised healthcare providers. These can include the diagnosis, medicines and allergies, specialist reports, investigations, treatment history and other information needed for the stated clinical question.

The request must explain the recipients, purpose, secure transfer method and any overseas handling before records are sent. Please do not provide another person’s health information without the necessary authority. A family relationship alone should not be assumed to authorise every disclosure.

4. Why information may be processed

Purposes may include answering an enquiry, checking professional identity, considering a medical review, arranging permitted clinical care, maintaining product traceability, safety follow-up, handling a complaint and meeting legal or regulatory duties. Only purposes that apply to the actual service should be retained in the final notice.

The organisation must identify the legal basis for each purpose. Where EU/EEA or UK rules apply, health information needs the relevant special-category condition as well as the general processing basis. Consent must not be treated as the automatic basis for every care, safety or legal obligation. [S16]

5. Who may receive information

Depending on the authorised activity, recipients may include the referring clinician, proposed treating institution, designated medical and safety reviewers, relevant quality personnel, approved service providers and authorities where reporting is required. The final notice must identify the actual entities or meaningful categories, their roles and the limits of access.

A general enquiry should not automatically be shared with every prospective clinic, commercial agent or referral partner. A referral, records review or treatment arrangement does not provide permission for advertising use.

6. International transfers

Your country of residence, the reviewing team, the treating institution and service providers may be in different countries. Before an international medical-record transfer, the applicable recipient countries, safeguards and any relevant patient authorisation must be explained.

The final notice must describe the actual transfer arrangement and how information about its safeguards can be obtained. A generic statement that “data may be transferred worldwide” is not a substitute for this assessment.

7. How long records are retained

Retention depends on the purpose and the applicable clinical, safety, quality and legal requirements. The final schedule must specify periods or meaningful criteria for general enquiries, declined or withdrawn reviews, professional verification, treatment records, safety/product-traceability records, consent and complaints.

[INSERT APPROVED RETENTION SCHEDULE AND CONTACT FOR QUESTIONS.] No arbitrary universal deletion period is promised. Some records may need to be retained after a person stops treatment or withdraws optional consent.

8. Security and providers

The proposed service should use access-limited systems, appropriate secure transfer, controlled permissions and documented vendor responsibilities. The final description must match the systems actually implemented and tested. No website can promise absolute security.

The service must not use health enquiries, patient records or professional case materials for advertising audiences, session-replay tracking or sale of personal information. This is a proposed operating policy that must be reflected in the actual technical implementation and contracts.

9. Your choices and rights

Depending on the law that applies, you may have rights to information about processing, access, correction, deletion, restriction, objection, portability or withdrawal of consent. Rights may be subject to exceptions for care, safety, legal duties or the rights of others.

Use [VERIFIED PRIVACY CONTACT] for a request. The team may need to verify your identity and authority. The final notice must identify the appropriate regulator or complaint route for the countries served; a patient need not use an internal complaint process where the law allows a direct regulatory complaint.

10. Separate permissions

An enquiry is not consent to treatment. Permission to obtain records is not permission to use your photograph or story. Optional research, secondary data use and any optional communications must be addressed separately through the appropriate process.

Declining marketing or publicity must not determine medical eligibility. No publicity programme or marketing opt-in is included in this initial website design.

11. Children, representatives and decision-making capacity

This website does not invite children to submit their own health records. A request concerning a child or a person needing a representative requires a verified legal and clinical process, appropriate information and any required consent or assent. This does not mean that a paediatric KHC programme exists.

12. Automated decisions, updates and local notices

No automated medical-eligibility decision or chatbot diagnosis is part of this prototype. Any future automation would require a separate assessment and disclosure before use.

The final notice should show its effective date, explain material changes and provide the relevant local supplement. It must not claim that HIPAA applies to every health-related website; the US entity and service roles determine whether HIPAA duties apply. Other privacy obligations may also apply. [S17]

This review edition

Navigation, page display and prototype controls run locally in the browser. The review files do not submit forms, load third-party fonts, embed advertising pixels or run analytics. The website image is supplied within the pack. External official-source links are opened only when selected.

This describes the supplied prototype, not an assurance about a future hosting provider or any tools added later.

The live website

Before launch, the operator must publish an accurate technology inventory covering cookies, local storage and similar tools. It must identify their purposes, providers and relevant lifetimes and distinguish necessary functions from optional analytics or other services.

Where consent is required, optional tools must remain off until a valid choice is made. Rejecting optional tools should be as straightforward as accepting them, and changing a choice should remain available.

Proposed privacy-first approach

No advertising pixels, behavioural retargeting or session recording should operate on medical enquiry, professional verification, secure record-transfer, safety or complaint pages. Sensitive information must not appear in URLs, campaign tags or analytics events.

A consent banner must reflect the tools actually used. This prototype does not show a misleading “accept all cookies” choice when no optional cookies are present.

More information

Read the privacy notice before providing personal information to any live service. External websites have their own privacy and technology arrangements.

Website operator and scope

This service is to be operated by [LEGAL ENTITY AND REGISTERED ADDRESS]. These website terms concern information and enquiries. Clinical care, consent, payment and any proposed treatment require separate agreements with the responsible provider.

This is a review prototype. It must not be used to submit real enquiries, place orders or make payments.

No medical advice or guarantee

The information is general and does not diagnose an illness, prescribe treatment or recommend KHC for any individual. A website interaction does not, by itself, establish a physician–patient relationship or entitlement to a review.

No guarantee of access, product availability, safety, efficacy, benefit, regulatory approval or timing is made. Do not discontinue prescribed care or delay urgent assessment because of website content.

Country-specific availability

The law and the relevant institution’s permissions determine whether a particular treatment can be considered. Selecting a country or reading an overseas page does not create permission to advertise, import, supply, prescribe or administer a product in another jurisdiction.

No purchase, treatment booking or automatic repeat-treatment arrangement is available through this website.

Accuracy and changes

Information may change as the product, evidence, country position or programme arrangements change. The responsible organisation must maintain a reviewed version and correct material inaccuracies. A website update cannot retroactively change a signed patient agreement or remove rights that the law protects.

Appropriate use

Do not submit another person’s confidential information without authority, upload material through an unapproved channel or use the website to seek urgent care. The operator’s response process must respect privacy and patient safety; these terms are not a substitute for those responsibilities.

Links, images and third parties

Official-source links are provided for context, not as evidence that an authority endorses the programme. Illustrations do not depict an actual patient, clinician, facility or clinical result unless explicitly verified and labelled as such.

Any travel, insurance or other third-party arrangement should be reviewed on its own terms. No third-party provider or outcome is guaranteed by this website.

Your legal rights

Nothing in these website terms should exclude liability or rights that cannot lawfully be excluded, waive patient protections or remove applicable consumer, privacy or regulatory remedies. Clinical and financial disputes must be addressed under the relevant agreement and applicable law.

[INSERT LOCALLY REVIEWED CONTACT, APPLICABLE-LAW AND DISPUTE PROVISIONS, PRESERVING MANDATORY PATIENT AND CONSUMER RIGHTS.] A universal foreign-law clause should not be assumed effective in every country.

A clinical or safety concern

For urgent symptoms, seek medical help immediately. For a non-urgent problem after treatment, contact the treating institution and the safety-reporting contact supplied in your patient documents. A complaint form is not a substitute for clinical assessment.

A service or financial complaint

You should be able to ask for an explanation about an enquiry, communication, charge or cancellation. The live service must identify the responsible complaints contact and explain how a complaint is acknowledged, reviewed and escalated.

Please include the relevant reference number, what happened, when it occurred and the response you are seeking. Do not send unrelated medical records or details of another patient.

A privacy concern

Use the privacy contact for a records or data-handling issue. You may also have a right to complain to the relevant authority. An internal process must not remove that right.

Fair handling

A complaint should not determine clinical eligibility, access to necessary safety information or the release of records to which you are entitled. Where a conflict of interest exists, an appropriately independent review should be arranged.

Review-edition notice: a live complaints contact, acknowledgement standard and escalation timetable have not yet been supplied. These must be published before the service is activated. No complaint is submitted through this prototype.

Reading and navigating

The proposed design uses clear headings, readable text, visible keyboard focus, labelled controls and layouts that adapt to smaller screens. Important information is written as text rather than being available only inside an image.

The development target is WCAG 2.2 Level AA. This is a target, not a claim that the prototype or a future live website has received an accessibility certification. A complete review of the deployed site and its forms is required. [S18]

Language support

This pack is the English master. It does not claim that Korean or other local-language versions have been completed or medically reviewed. Before a country programme is released, the relevant local content and patient documents need appropriate translation and review.

Patients should not be asked to consent to treatment using documents they do not understand. The treating institution should explain what interpretation or translation can be provided and any associated charges.

Request another format

A live service should provide a working contact for accessible formats and communication assistance. Requests should ask what would help, rather than require a person to disclose unnecessary medical detail.

[INSERT VERIFIED ACCESSIBILITY CONTACT AND RESPONSE PROCESS.] This prototype does not accept requests. A difficulty using the website should not prevent someone from obtaining appropriate clinical or safety information through an alternative channel.

What does this service do?

It provides general administrative information and a route for healthcare professionals to request an appropriate factual response. It does not diagnose conditions, recommend treatment or book clinical care.

Can I upload my medical records?

Not through the general enquiry page. Where further review is appropriate, a responsible professional must explain the authorised process and privacy arrangements first.

Can a family member ask a question?

Anyone may ask a general administrative question. Sharing identifiable information or acting on a patient’s behalf requires the appropriate authority.

Will a reply mean I have been accepted for treatment?

No. An information response does not establish eligibility, local availability, a clinical relationship or permission to receive a particular intervention.

Can I pay through this website?

No. This website does not sell treatment, take deposits or offer priority review for a fee.

What about an urgent medical concern?

Seek local medical help or contact the clinical team responsible for your existing care. Do not wait for an administrative response.

Does this prototype send enquiries?

No. All forms in the review edition are disabled and no message is submitted or stored.

Current project description

KHC is described in the project as an allogeneic cellular product derived from umbilical-cord tissue. No genetic modification is reported. The term “undifferentiated” appears in project descriptions, but the exact current phenotype and identity panel have not been established in the reviewed website source package.

Do not relabel the product as a defined mesenchymal stromal-cell population, pluripotent population, cord-blood transplant, exosome preparation or another product category without the supporting current dossier.

Information required for the product version under review

Source and traceability: donor consent and eligibility, procurement, donor-to-bank-to-lot genealogy and relevant testing.

Identity and composition: the defined cell population, identity markers and acceptance criteria, viable-cell count, concentration, formulation, excipients and container closure.

Manufacture and quality: the actual manufacturer and site, current permissions, process controls, specifications, representative batch data, deviations and applicable microbial, endotoxin, mycoplasma, identity, viability and potency information.

Storage and handling: approved shelf life, qualified shipping conditions, receipt and excursion procedures, preparation/thaw instructions and in-use limits.

Clinical presentation: indication-specific dose, route, schedule, administration technique, monitoring and repeat-treatment criteria. Commercial planning configurations must not be used as dosing instructions.

Limits of the current information

The project reports existing GMP manufacture and CMC information in Korea. This website pack does not verify the current licence, complete CMC dossier, suitability of every batch or comparability between the historical and current product.

An available stock balance does not establish an acceptable shelf life, released status or suitability for a particular patient. A positive medical review must never override an unresolved product-quality issue.

Release rule

No treatment may be authorised from this summary. The responsible medical, quality and regulatory teams require the controlled current information and the actual lot disposition. Unresolved facts must be disclosed rather than filled with an assumed value.

Reported Korean clinical experience

Management reports approximately 30 years of clinical-use experience in Korea. Its value depends on source-verifiable patient records, denominators, follow-up completeness, concurrent care and a reliable link to the product version administered.

A coherent assessment needs all traceable patients in a defined cohort, not selected favourable outcomes. Missing records, deaths, hospitalisations, discontinuations and loss to follow-up must be reconciled. Earlier use cannot automatically establish safety or efficacy of the current product.

External publications and related platforms

Published work on umbilical-cord cellular approaches can provide scientific context. It is not product-specific evidence unless identity, manufacture, composition, route and relevant comparability are demonstrated. Work from a related organisation must not be treated as KHC evidence solely because of a commercial or scientific relationship.

Risk information for professional review

The product-specific risk assessment remains dependent on the completed dossier and proposed use. The project’s review domains include infection and contamination, infusion or injection reactions, immune effects, vascular or thrombotic events, unintended tissue formation, malignancy concerns, neurological deterioration where relevant, and unknown or delayed effects.

These are assessment and monitoring domains, not established KHC event frequencies or a claim that each has occurred. Equally, an absence of documented reports is not proof that a risk is absent. The final patient information must distinguish observed findings, plausible risks and unresolved uncertainties.

Condition-specific work

Diabetes-related chronic lower-extremity wound and vascular review is a worked example in the latest patient and clinician packs. It is not a verified authorised indication or evidence that KHC closes wounds, restores perfusion or prevents amputation.

Any clinical review must address infection, current perfusion, standard wound care and whether established specialist intervention remains indicated. Other therapeutic areas discussed in planning require their own evidence, criteria and clinical plan. The separate AML-vaccine concept must not be merged with KHC product claims.

Required professional conclusion

Explain what the evidence supports, what it does not support and what additional information would change the recommendation. Record the alternative options and the reasons to proceed, defer or decline. No patient decision should be based on an uncontrolled success story or a commercial forecast.

The clinical request

Provide a patient programme identifier; confirmed diagnosis, duration and severity; the specific reason for review; previous and current treatments with response; established options still available; relevant comorbidities, medicines, allergies and recent hospitalisations; and the patient’s ability to participate in necessary follow-up.

Include relevant dated investigations and specialist assessments. For a diabetic lower-extremity wound review, the project example requires the current wound assessment, infection evaluation, off-loading and standard-care history, and objective vascular/perfusion assessment where clinically appropriate. Urgent infection or threatened circulation must remain in the usual urgent-care pathway.

Patient permission

Confirm the patient or appropriate representative has authorised the necessary review and record disclosure. Explain the recipients, country transfers and privacy information before records are sent. Do not attach identifiable files to an unverified email address or a general website form.

Possible review outcomes

Further review: information is sufficient to begin the remaining medical and programme assessments. This is not final treatment acceptance.

Deferred: specified additional information or clinical assessment is needed. The unresolved issue and next step must be clear.

Unable to offer access: the clinical rationale, evidence, country route, product, facility, financial or safety/data requirements are not met. Communicate the outcome without implying that payment could change it.

Before administration

Final clearance requires the current clinical decision, lawful country route, named qualified institution and physician, informed consent, approved financial disclosure, released product, patient–lot reconciliation and a monitoring and emergency plan. Product receipt and preparation records must be completed by the responsible team.

Follow-up and repeat decisions

The plan should identify the treating and home-clinician responsibilities, immediate contact, scheduled assessments, clinically relevant outcomes, adverse-event reporting and longer-term monitoring. Do not assume that a patient returning home ends the programme’s safety responsibilities.

A repeat administration requires a fresh decision based on current health, observed response and safety, product status, continuing legal permission and the patient’s informed choice. Forecast repeat-block uptake is not a clinical recommendation.

Review and authorisation

KHC-ACC-01 — Clinician request: the clinical question, history, options, relevant records and referring professional.

KHC-ACC-02 — Record-review authorisation: permitted sources, recipients and information; not treatment or publicity consent.

KHC-ACC-03 — Preliminary eligibility: required clinical information, potential exclusions and reasons to defer.

KHC-ACC-04 — Independent benefit–risk review: evidence, alternatives, uncertainties and documented recommendation.

Country, institution and decision

KHC-ACC-05 — Country and payment clearance: exact route, permissions, importer/supply responsibilities and charging position.

KHC-ACC-06 — Facility readiness: qualified personnel, product handling, emergency arrangements, monitoring and training.

KHC-ACC-07 — Consent-readiness discussion: evidence, limitations, risks, alternatives, costs, follow-up, questions and the patient’s choice. It does not replace the final treatment consent.

KHC-ACC-08 — Patient quotation: named payees, currencies, product/access charge if permitted, shipping, clinical/facility fees, tests, follow-up, travel, taxes and potential additional costs. Include medical/product/provider/patient cancellation, complication costs and repeat-treatment terms.

Administration and follow-up

KHC-ACC-09 — Receipt and administration: patient allocation, lot and expiry, accepted temperature record, quality release, preparation, actual dose/route/time, observations and reconciliation.

KHC-ACC-10 — Safety and quality report: event, timing, reporter, treatment and lot if known, seriousness and follow-up. Urgent action must not wait for a completed form.

KHC-ACC-11 — Follow-up record: new events, concurrent treatments, clinical findings and relevant objective outcomes, with dates and sources.

KHC-ACC-12 — Repeat-treatment review: new medical, safety and quality decision; continuing permissions; patient choice and updated costs.

Document control

Each form needs an owner, version, effective date, approved country/programme scope, access rights and retention rule. A completed form is not a substitute for the required sign-offs. The latest project versions are examples and must be adapted and approved before operational use.